FindTrial
Sign In

Effect of Recombinant Human Brain Natriuretic Peptide on Preventing Acute Kidney Injury (AKI) in high risk patients: a pilot randomized controlled trial

Effect of Recombinant Human Brain Natriuretic Peptide on Preventing Acute Kidney Injury (AKI) in high risk patients: a pilot randomized controlled trial

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2000035248
Enrollment
Unknown
Registered
2020-08-05
Start date
2020-08-10
Completion date
Unknown
Last updated
2024-09-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Acute Kidney Injury

Interventions

experimental group:rhBNP therapy
control group:placebo therapy

Sponsors

Sun Yat-Sen University First Affiliated Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to No maximum

Inclusion criteria

Inclusion criteria: 1. Aged >= 18 years; 2. High-risk patients without AKI.

Exclusion criteria

Exclusion criteria: 1. Have a history of solid organ or bone marrow transplantation; 2. Pregnancy or lactation patients; 3. Systolic pressure < 90 mmHg; 4. Allergic history or intolerant to rhBNP; 5. Decide to cease or give up life support in artificial ways; 6. Expected ICU stay < 48 h; 7. Administration of diuretics during the screening period; 8. Cardiopulmonary resuscitation occurred within 72 hours and neurological function has not recovered; 9. Chronic renal insufficiency that requires long-term dialysis; 10. A terminal state of disease with an expected high mortality; 11. Being enrolled by other studies; 12. Those who have not done relevant tests within 24 hours.

Design outcomes

Primary

MeasureTime frame
Enrolled patints within one year;The fesibility of the protocal;—

Secondary

MeasureTime frame
the proportion of patients with high AKI risk in ICU patients in this region;Incidence of AKI within 7 days;The proportion of drug use time reaching 72h;The proportion of different stage of AKI;28 day all-cause mortality;Daily fluid balance;Daily dose of furosemide;Daily total dose of Norepinephrine;Hourly urine output;The change of electrolyte acid-base balance;The change of NGAL;The change of KIM-1;The change of NT-proBNP;Length of ICU stay;Proportion of new renal replacement therapy;Length of hospital stay;ICU mortality;Hospital mortality;28 day mechanical ventilation free time;28 day ICU free time;28 day RRT free time;28 day vasopressors free time;28 day diuretics free time;28 day inotropic agents free time;Renal resisttance index;Renal blood level;multi-omics analysis;—

Countries

China

Contacts

Public ContactWu Jianfeng

The First Affiliated Hospital, Sun Yat-Sen University

wujianfeng9571@163.com+86 189 8893 8255

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026